FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2885200747> ?p ?o ?g. }

• W2885200747 endingPage "3995" @default.
• W2885200747 startingPage "3995" @default.
• W2885200747 abstract "Abstract Introduction: Lung cancer is the second most common diagnosed malignancy and accounts for the biggest number of cancer related deaths worldwide. Despite increased health warnings associated with habits, such as smoking, ten year survival rates for lung cancer in the UK remain similar to those seen in the 1970's. In the USA, the 5 year survival rates dramatically reduce with late disease stage, from 49 percent at Stage 1A to 5 percent at Stage IIIB. Mutations in epidermal growth factor receptor (EGFR) appears to be quite common in lung cancer. ERBB2 mutations also appear, albeit at lower frequency. In addition, ERBB2 amplifications have also been reported, particularly in tumors that have become resistant to EGFR-TKIs. Neratinib is an orally available tyrosine kinase inhibitor that irreversibly binds and inhibits EGFR, ERBB2 and ERBB4 receptor tyrosine kinases. This study aimed to characterize in detail the expression profile of genes downstream of the EGFR family members in two NSCLC cell lines and their differential sensitivity to neratinib. Materials and Methods: A549 (adenocarcinoma), a cell line with intermediate sensitivity to gefitnib, and SKMES-1 (squamous cell carcinoma) NSCLC cell lines were purchased from American Tissue Culture Collection (ATCC). Cytotoxicity was assessed using an MTT assay. Changes in gene expression in response to neratinib were quantified by next generation sequencing using AmpliSeq technology and analysed using Ingenuity pathway analysis (IPA) software. Results: SKMES-1 lung cancer cells were found to be more sensitive to neratinib than A549 cancer cells. Both cell lines exhibited similar low gene expression levels of ERBB2. SKMES-1 cancer cells showed higher gene expression profiles for the remaining HER family members, EGFR, ERBB3 and ERBB4, compared to the A549 cancer cells. IPA analysis showed that in SKMES-1 cells treated with neratinib differentially expressed genes were associated with inhibition of Akt and ERK pathways and their signal transduction whereas, this was not seen in the A549 cells. Conclusions: This study has shown that although these two NSCLC cell lines have similar gene expression levels of ERBB2, there is a difference in profile amongst the other receptor family members. EGFR and ERBB4 mRNA transcript levels were twice as high in SK-MES-1 compared to A549. This variance in the ERBB family gene expression profile may account for the differing sensitivities these cell lines have to neratinib. Further analysis indicates that Akt/ERK signal transduction was inhibited in SKMES-1 cells treated with neratinib though the exact mechanism for this remains unknown. Citation Format: Sioned Owen, Dafydd A. Dart, Alshad S. Lalani, Francesca Avogadri-Connors, Richard P. Bryce, Wen G. Jiang. Exploring non-small cell lung carcinoma cell lines' sensitivity to neratinib [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 3995." @default.
• W2885200747 created "2018-08-22" @default.
• W2885200747 creator A5007997858 @default.
• W2885200747 creator A5015057915 @default.
• W2885200747 creator A5017993198 @default.
• W2885200747 creator A5029616157 @default.
• W2885200747 creator A5041647199 @default.
• W2885200747 creator A5085464902 @default.
• W2885200747 date "2018-07-01" @default.
• W2885200747 modified "2023-09-27" @default.
• W2885200747 title "Abstract 3995: Exploring non-small cell lung carcinoma cell lines' sensitivity to neratinib" @default.
• W2885200747 doi "https://doi.org/10.1158/1538-7445.am2018-3995" @default.
• W2885200747 hasPublicationYear "2018" @default.
• W2885200747 type Work @default.
• W2885200747 sameAs 2885200747 @default.
• W2885200747 citedByCount "0" @default.
• W2885200747 crossrefType "journal-article" @default.
• W2885200747 hasAuthorship W2885200747A5007997858 @default.
• W2885200747 hasAuthorship W2885200747A5015057915 @default.
• W2885200747 hasAuthorship W2885200747A5017993198 @default.
• W2885200747 hasAuthorship W2885200747A5029616157 @default.
• W2885200747 hasAuthorship W2885200747A5041647199 @default.
• W2885200747 hasAuthorship W2885200747A5085464902 @default.
• W2885200747 hasConcept C101544691 @default.
• W2885200747 hasConcept C121608353 @default.
• W2885200747 hasConcept C126322002 @default.
• W2885200747 hasConcept C143998085 @default.
• W2885200747 hasConcept C170493617 @default.
• W2885200747 hasConcept C184235292 @default.
• W2885200747 hasConcept C2776256026 @default.
• W2885200747 hasConcept C2779413316 @default.
• W2885200747 hasConcept C2779438470 @default.
• W2885200747 hasConcept C2779786085 @default.
• W2885200747 hasConcept C2781182431 @default.
• W2885200747 hasConcept C42362537 @default.
• W2885200747 hasConcept C502942594 @default.
• W2885200747 hasConcept C530470458 @default.
• W2885200747 hasConcept C54355233 @default.
• W2885200747 hasConcept C71924100 @default.
• W2885200747 hasConcept C86803240 @default.
• W2885200747 hasConceptScore W2885200747C101544691 @default.
• W2885200747 hasConceptScore W2885200747C121608353 @default.
• W2885200747 hasConceptScore W2885200747C126322002 @default.
• W2885200747 hasConceptScore W2885200747C143998085 @default.
• W2885200747 hasConceptScore W2885200747C170493617 @default.
• W2885200747 hasConceptScore W2885200747C184235292 @default.
• W2885200747 hasConceptScore W2885200747C2776256026 @default.
• W2885200747 hasConceptScore W2885200747C2779413316 @default.
• W2885200747 hasConceptScore W2885200747C2779438470 @default.
• W2885200747 hasConceptScore W2885200747C2779786085 @default.
• W2885200747 hasConceptScore W2885200747C2781182431 @default.
• W2885200747 hasConceptScore W2885200747C42362537 @default.
• W2885200747 hasConceptScore W2885200747C502942594 @default.
• W2885200747 hasConceptScore W2885200747C530470458 @default.
• W2885200747 hasConceptScore W2885200747C54355233 @default.
• W2885200747 hasConceptScore W2885200747C71924100 @default.
• W2885200747 hasConceptScore W2885200747C86803240 @default.
• W2885200747 hasIssue "13_Supplement" @default.
• W2885200747 hasLocation W28852007471 @default.
• W2885200747 hasOpenAccess W2885200747 @default.
• W2885200747 hasPrimaryLocation W28852007471 @default.
• W2885200747 hasRelatedWork W2031328554 @default.
• W2885200747 hasRelatedWork W2055903396 @default.
• W2885200747 hasRelatedWork W2134171958 @default.
• W2885200747 hasRelatedWork W2367971684 @default.
• W2885200747 hasRelatedWork W2624131070 @default.
• W2885200747 hasRelatedWork W2752751742 @default.
• W2885200747 hasRelatedWork W2901521863 @default.
• W2885200747 hasRelatedWork W2955702246 @default.
• W2885200747 hasRelatedWork W3030541392 @default.
• W2885200747 hasRelatedWork W4361253018 @default.
• W2885200747 hasVolume "78" @default.
• W2885200747 isParatext "false" @default.
• W2885200747 isRetracted "false" @default.
• W2885200747 magId "2885200747" @default.
• W2885200747 workType "article" @default.